FDA Puts Investigational DM1 Therapy AOC 1001 on Fast Track

FDA Puts Investigational DM1 Therapy AOC 1001 on Fast Track

309484

FDA Puts Investigational DM1 Therapy AOC 1001 on Fast Track

The U.S. Food and Drug Administration (FDA) has granted fast track designation to AOC 1001, an investigational treatment for myotonic dystrophy type 1, known as DM1, a late-developing muscle disorder. The designation will enable AOC 1001’s developer, Avidity Biosciences, to have more frequent interactions with the FDA throughout the development process. The overall goal of the FDA’s fast track program is to expedite the review of therapies that have the potential to improve care for serious…

You must be logged in to read/download the full post.